Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer

详细信息    查看全文

• 作者：Matthew D Schmitz (1)
  Gilbert DA Padula (2) (3)
  Patrick Y Chun (1)
  Alan T Davis (4) (5)
  
• 刊名：Radiation Oncology
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：5
• 期：1
• 全文大小：252KB
• 参考文献：1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. / CA Cancer J Clin 2009, 59:225-49. CrossRef
  2. Zelefsky MJ, Fuks Z, Leibel SA: Intensity-modulated radiation therapy for prostate cancer. / Semin Radiat Oncol 2002, 12:229-37. CrossRef
  3. Leibel SA, Fuks Z, Zelefsky MJ, Wolden SL, Rosenzweig KE, Alektiar KM, Hunt MA, Yorke ED, Hong LX, Amols HI, Burman CM, Jackson A, Mageras GS, LoSasso T, Happersett L, Spirou SV, Chui CS, Ling CC: Intensity-modulated radiotherapy. / Cancer J 2002, 8:164-76. CrossRef
  4. Perez CA, Michalski JM, Purdy JA, Lockett MA: New trends in prostatic cancer research. Three-dimensional conformal radiation therapy (3-D CRT), brachytherapy, and new therapeutic modalities. / Rays 2000, 25:331-43.
  5. Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Padhani AR, Webb S, Dearnaley DP: Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. / Int J Radiat Oncol Biol Phys 2000, 48:649-56. CrossRef
  6. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. / N Engl J Med 1997, 337:295-00. CrossRef
  7. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Grignon D, Caplan R, Cox JD, Soloway MS: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. / Urology 1995, 45:616-23. CrossRef
  8. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. / N Engl J Med 1991, 324:1156-161. CrossRef
  9. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. / J Urol 1989, 142:1011-017.
  10. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. / Int J Radiat Oncol Biol Phys 1997, 37:1035-041.
  11. Roach M, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. / Int J Radiat Oncol Biol Phys 2006, 65:965-74. CrossRef
  12. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. / J Urol 1992, 147:956-61.
  13. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley EL Jr: Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. / Int J Cancer 1991, 49:645-49. CrossRef
  14. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP: Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. / Urology 2000, 56:527-32. CrossRef
  15. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkman AO, Trapman J: The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. / Mol Endocrinol 1991, 5:1921-930. CrossRef
  16. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkman AO, Trapman J: Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. / J Biol Chem 1996, 271:6379-388. CrossRef
  17. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH, European Organisation for Research and Treatment of Cancer; Limburgs Universitair Centrum; AstraZeneca Pharmaceuticals: Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. / J Clin Onc 2005, 23:6139-148. CrossRef
  18. Chung CS, Chen M-H, Cullen J, McLeod D, Carroll P, D'Amico AV: Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. / Urology 2008, 71:136-40. CrossRef
  19. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA: PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. / Int J Radiat Oncol Biol Phys 2006, 64:1140-150. CrossRef
  20. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ: Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. / J Cancer Res Clin Oncol 2010, in press.
  21. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G: Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. / Int J Radiat Oncol Biol Phys 2009, 73:327-33. CrossRef
  22. Zapatero A, Valcarcel F, Calvo FA, Algas R, Bejar A, Maldonado J, Villa S: Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. / J Clin Oncol 2005, 23:6561-568. CrossRef
  23. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-1. / Int J Radiat Oncol Biol Phys 2005, 61:1285-290. CrossRef
  
• 作者单位：Matthew D Schmitz (1)
  Gilbert DA Padula (2) (3)
  Patrick Y Chun (1)
  Alan T Davis (4) (5)
  
  1. College of Human Medicine, Michigan State University, East Lansing, MI, USA
  2. Department of Medicine, Michigan State University College of Human Medicine, East Lansing, Michigan, USA
  3. Lacks Cancer Center, Saint Mary's Health Care, Grand Rapids, Michigan, USA
  4. Department of Surgery, Michigan State University, Grand Rapids, MI, USA
  5. Department of Research, Grand Rapids Medical Education Partners, Grand Rapids, MI, USA
  

文摘

Background The purpose of this study was to determine the expected time to prostate specific antigen (PSA) normalization with or without neoadjuvant androgen deprivation (NAAD) therapy after treatment with intensity modulated radiotherapy (IMRT) for patients with clinically localized prostate cancer. Methods A retrospective cohort research design was used. A total of 133 patients with clinical stage T1c to T3b prostate cancer (2002 AJCC staging) treated in a community setting between January 2002 and July 2005 were reviewed for time to PSA normalization using 1 ng/mL and 2 ng/mL as criteria. All patients received IMRT as part of their management. Times to PSA normalization were calculated using the Kaplan-Meier method. Significance was assessed at p < 0.05. Results Fifty-six of the 133 patients received NAAD (42.1%). Thirty-one patients (23.8%) received radiation to a limited pelvic field followed by an IMRT boost, while 99 patients received IMRT alone (76.2%). The times to serum PSA normalization < 2 ng/mL when treated with or without NAAD were 298 ± 24 and 302 ± 33 days (mean ± SEM), respectively (p > 0.05), and 303 ± 24 and 405 ± 46 days, respectively, for PSA < 1 ng/mL (p < 0.05). Stage T1 and T2 tumors had significantly increased time to PSA normalization < 1 ng/mL in comparison to Stage T3 tumors. Also, higher Gleason scores were significantly correlated with a faster time to PSA normalization < 1 ng/mL. Conclusions Use of NAAD in conjunction with IMRT leads to a significantly shortened time to normalization of serum PSA < 1 ng/mL in patients with clinically localized prostate cancer.